Completed PHASE2 INTERVENTIONAL 1-arm NCT01083602

Efficacy of Panobinostat in Patients With Relapsed and Bortezomib-refractory Multiple Myeloma (MACS1271)

A Phase II, Multi-center, Single Arm, Open Label Study of Panobinostat in Combination With Bortezomib and Dexamethasone in Patients With Relapsed and Bortezomib-refractory Multiple Myeloma

Sponsor: Novartis Pharmaceuticals

Conditions Multiple Myeloma in Relapse Refractory Multiple Myeloma Relapsed and Bortezomib Refractory Multiple Myeloma

Interventions bortezomib dexamethasone panobinostat

Updated 8 times since 2017 Last updated: Nov 27, 2017 Started: Jun 30, 2010 Primary completion: Feb 28, 2014 Completion: Feb 28, 2014

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT01083602, this PHASE2 trial focuses on Multiple Myeloma in Relapse and Refractory Multiple Myeloma and remains completed. Sponsored by Novartis Pharmaceuticals, it has been updated 8 times since 2010, reflecting limited change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.

Status Flow

Change History

8 versions recorded

Sep 2025 — Present [monthly]

Completed PHASE2
Sep 2024 — Sep 2025 [monthly]

Completed PHASE2
Jul 2024 — Sep 2024 [monthly]

Completed PHASE2
Jan 2021 — Jul 2024 [monthly]

Completed PHASE2
Jun 2018 — Jan 2021 [monthly]

Completed PHASE2

▶ Show 3 earlier versions

Jan 2018 — Jun 2018 [monthly]

Completed PHASE2

Phase: PHASE4 → PHASE2
Feb 2017 — Jan 2018 [monthly]

Completed PHASE4
Jan 2017 — Feb 2017 [monthly]

Completed PHASE4

First recorded

Jun 2010

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Novartis Pharmaceuticals

Data source: Novartis

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Atlanta, United States , Augusta, United States , Boston, United States , Durham, United States , Houston, United States , Los Angeles, United States , Milwaukee, United States , Nashville, United States , Skokie, United States , Somerset, United States and 3 more locations